Post-infarct cardiac injury, protection and repair: roles of non-cardiomyocyte multicellular and acellular components

• Published in: Science China. Life sciences 2018-03, Vol.61 (3), p.266-276
• Main Author: Du, Xiaojun
• Format: Article
• Language: English
• Subjects: Animals; Biomedical and Life Sciences; Cardiomyocytes; Clinical trials; Extracellular matrix; Extracellular Matrix - pathology; Heart; Heart - innervation; Heart - physiology; Heart - physiopathology; Heart diseases; Humans; Immunity, Innate - immunology; Inflammation; Innate immunity; Ischemia; Life Sciences; Lymphatic Vessels - pathology; Lymphatic Vessels - physiopathology; Microvasculature; Microvessels - pathology; Microvessels - physiopathology; Myocardial infarction; Myocardial Infarction - pathology; Myocardial Infarction - physiopathology; Myocardial Infarction - therapy; Myocardial Reperfusion - adverse effects; Myocardial Reperfusion - standards; Myocardium - immunology; Myocardium - pathology; Regeneration - physiology; Reperfusion; Review; Stem cells; Ventricular Remodeling - immunology; Ventricular Remodeling - physiology
• ISSN: 1674-7305; 1869-1889
• DOI: 10.1007/s11427-017-9223-x

Following myocardial infarction (MI), cardiomyocytes and infarct size are the focus of our attention when evaluating the extent of cardiac injury, efficacy of therapies or success in repairing the damaged heart by stem cell therapy. Numerous interventions have been shown by pre-clinical studies to be effective in limiting infarct size, and yet clinical trials designed accordingly have yielded disappointing outcomes. The ultimate goal of cardiac protection is to limit the adverse cardiac remodeling. Accumulating studies have revealed that post-infarct remodeling can be attenuated without infarct size limitation. To reconcile this, one needs to appreciate the significance of various cellular and acellular myocardial components that, like cardiomyocytes, undergo significant damage and dysfunction, which impact the ultimate cardiac injury and remodelling. Microvascular injury following ischemia-reperfusion may influence infarct size and promote inflammation. Myocardial injury evokes innate immunity with massive inflammatory infiltration that, although essential for the healing process, exacerbates myocardial injury and damage to extracellular matrix leading to dilative remodeling. It is also important to consider the multiple non-cardiomyocyte components in evaluating therapeutic efficacy. Current research indicates the pivotal role of these components in achieving cardiac regeneration by cell therapy. This review summarizes findings in this field, highlights a broad consideration of therapeutic targets, and recommends cardiac remodeling as the ultimate target.